Hydrocortisone or pasireotide to prevent complications after pancreatic surgery

• Conditions: Patients undergoing pancreatic resection.; Therapeutic area: Diseases [C] - Digestive System Diseases [C06]

• Registration Number: EUCTR2016-000212-16-FI
• Lead Sponsor: Helsinki University Central Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-03-30
• Last Update Posted: 18 April 2016

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients undergoing pancreatic resection.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 80
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 44

Exclusion Criteria

- Atrophic pancreas, dilated main pancreatic duct at the site of pancreaticojejunostomy
- Total pancreatectomy
- Allergy to studied medications
- Age < 18 years
- No written consent
- Pancreatic resection not performed, even if planned
- Hard pancreas/dilated main pancreatic duct (only patients undergoing PD)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified